INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 157 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q3 2023. The put-call ratio across all filers is 2.78 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2015 | $6,795,000 | -12.8% | 40,971 | +26.9% | 0.15% | -13.1% |
| Q2 2015 | $7,791,000 | -12.5% | 32,281 | +2.2% | 0.17% | -9.7% |
| Q1 2015 | $8,904,000 | +259.6% | 31,574 | +98.9% | 0.19% | +244.4% |
| Q4 2014 | $2,476,000 | -2.6% | 15,874 | +47.8% | 0.05% | -5.3% |
| Q3 2014 | $2,542,000 | +68.3% | 10,740 | +68.3% | 0.06% | +72.7% |
| Q2 2014 | $1,510,000 | +68.7% | 6,380 | +135.2% | 0.03% | +65.0% |
| Q1 2014 | $895,000 | +0.6% | 2,713 | -79.2% | 0.02% | +5.3% |
| Q4 2013 | $890,000 | – | 13,039 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sarissa Capital Management LP | 635,300 | $53,308,000 | 10.69% |
| Senvest Management, LLC | 976,127 | $81,907,000 | 5.65% |
| Melqart Asset Management (UK) Ltd | 390,600 | $32,775,000 | 2.80% |
| Asymmetry Capital Management, L.P. | 25,918 | $2,175,000 | 2.14% |
| Elk Creek Partners, LLC | 386,397 | $32,423,000 | 1.78% |
| BB BIOTECH AG | 545,719 | $45,791,000 | 1.32% |
| ALTRINSIC GLOBAL ADVISORS LLC | 383,166 | $32,151,000 | 1.27% |
| DLD Asset Management, LP | 129,000 | $10,824,000 | 0.82% |
| Opus Point Partners Management, LLC | 3,998 | $335,000 | 0.73% |
| Virtus ETF Advisers LLC | 8,970 | $753,000 | 0.67% |